SCHEMBL4133591

SCHEMBL4133591

COc1ccc2cc(/C=C3\SC(Nc4ccc(CC(=O)O)cc4)=NC3=O)ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 10/20 0.50
PTGS1 P23219 1/20 0.48
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
HDAC4 P56524 2/20 0.45
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
PDE4B Q07343 1/20 0.42
PDE4D Q08499 1/20 0.42
MEN1 O00255 1/20 0.42
MITF O75030 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133593 1.00 ALOX5 (0.50) ALOX5PTGS1AKR1C3AKR1C2HDAC4
SCHEMBL4133440 0.91 ALOX5 (0.54) ALOX5HDAC4KDM4EHDAC8MEN1
SCHEMBL4120834 0.91 S1PR1 (0.41) ALOX5HDAC4HDAC8
SCHEMBL4120838 0.91 S1PR1 (0.41) ALOX5HDAC4HDAC8
SCHEMBL4133434 0.91 ALOX5 (0.54) ALOX5HDAC4KDM4EHDAC8MEN1
SCHEMBL4134114 0.90 PTPN22 (0.51) ALOX5HDAC4HDAC8
SCHEMBL4134117 0.90 PTPN22 (0.51) ALOX5HDAC4HDAC8
SCHEMBL4140267 0.88 ALOX5 (0.47) ALOX5PDE4BPDE4DMEN1RAB9A
SCHEMBL4140263 0.88 ALOX5 (0.47) ALOX5PDE4BPDE4DMEN1RAB9A
SCHEMBL4137396 0.87 ALOX5 (0.38) ALOX5POLBMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885PTGS1 946/4885AKR1C3 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.